Erlotinib in Higher Risk Myelodysplastic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01085838
Recruitment Status : Completed
First Posted : March 12, 2010
Last Update Posted : November 8, 2016
Roche Pharma AG
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : March 2014
  Study Completion Date : March 2014